Ejhg2009104.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
September-Sunshine-Line-2021
The Sunshine 186 Main St STE 2 * Brookville, PA 15825 Phone:(814) 849-3096 1-800-852-8036 Line www.jcaaa.org Find us on Facebook: @JeffersonCountyAAA Want to receive our newsletter by email? Volume 7 Issue 9 September 2021 Register on our website or call us! FREE Community Workshop Presentation: Get Ready for Medicare: The Basics for People Who are Joining Already r Enrolled Jefferson County Area Agency on Aging Medicare Education and Decision Insight Program September 8th 6:00pm-7:00pm Brookville Heritage House September 16th 10:00am-11:00am Punxy Area Senior Center September 17th 11:00am-12:00pm Reynoldsville Foundry Senior Center September 22nd 11:00am-12:00pm Brockway Depot Senior Center Call Mindy at 814-849-3096 Ext 232 to sign up What is Medicare Education and Decision Insight (PA-MEDI) Medicare Education and Decision Insight (PA MEDI) is the State Health Insurance Assistance Program in Pennsylvania. We provide free, unbiased insurance counseling to people on Medicare. PA MEDI counselors are specifically trained to answer any questions about your coverage.We provide you with clear, easy to understand information about your Medicare options and can assist in comparing plans. We will also screen you to see if you qualify for any financial assistance programs to get help paying for your prescription drugs or Part B premium. You will have a better understanding of: • Medicare • Part A, B and C • An Advantage Plan • Savings programs • How to avoid penalties • And much more 2 September 2021 Pennsylvania 211: Get Connected. Get Help. ™ If you need to connect with resources in your community, but don’t know where to look, PA 211 is a great place to start. -
Dermatologic Findings in 16 Patients with Cockayne Syndrome and Cerebro-Oculo-Facial-Skeletal Syndrome
Research Case Report/Case Series Dermatologic Findings in 16 Patients With Cockayne Syndrome and Cerebro-Oculo-Facial-Skeletal Syndrome Eric Frouin, MD; Vincent Laugel, MD, PhD; Myriam Durand, MSc; Hélène Dollfus, MD, PhD; Dan Lipsker, MD, PhD Supplemental content at IMPORTANCE Cockayne syndrome (CS) and cerebro-oculo-facial-skeletal (COFS) syndrome jamadermatology.com are autosomal recessive diseases that belong to the family of nucleotide excision repair disorders. Our aim was to describe the cutaneous phenotype of patients with these rare diseases. OBSERVATIONS A systematic dermatologic examination of 16 patients included in a European study of CS was performed. The patients were aged 1 to 28 years. Six patients (38%) had mutations in the Cockayne syndrome A (CSA) gene, and the remaining had Cockayne syndrome B (CSB) gene mutations. Fourteen patients were classified clinically as having CS and 2 as having COFS syndrome. Photosensitivity was present in 75% of the patients and was characterized by sunburn after brief sun exposure. Six patients developed symptoms after short sun exposure through a windshield. Six patients had pigmented macules on sun-exposed skin, but none developed a skin neoplasm. Twelve patients (75%) displayed cyanotic acral edema of the extremities. Eight patients had nail dystrophies and 7 had hair anomalies. CONCLUSIONS AND RELEVANCE The dermatologic findings of 16 cases of CS and COFS Author Affiliations: Author syndrome highlight the high prevalence of photosensitivity and hair and nail disorders. affiliations are listed at the end of this Cyanotic acral edema was present in 75% of our patients, a finding not previously reported article. in CS. Corresponding Author: Eric Frouin, MD, Service d’Anatomie et Cytologie Pathologiques, Université de JAMA Dermatol. -
Digital Clubbing
Review Article Digital clubbing Malay Sarkar, D. M. Mahesh1, Irappa Madabhavi2 Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, 1Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 2Post Graduate Student (Medicine), Indira Gandhi Medical College, Shimla, India ABSTRACT Digital clubbing is an ancient and important clinical signs in medicine. Although clubbed fingers are mostly asymptomatic, it often predicts the presence of some dreaded underlying diseases. Its exact pathogenesis is not known, but platelet‑derived growth factor and vascular endothelial growth factor are recently incriminated in its causation. The association of digital clubbing with various disease processes and its clinical implications are discussed in this review. KEY WORDS: Cancer, digital clubbing, hypertrophic osteoarthropathy, megakaryocytes, vascular endothelial growth factor Address for correspondence: Dr. Malay Sarkar, Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla ‑ 171 001, India. E‑mail: [email protected] INTRODUCTION long bones and occasional painful joint enlargement. It was initially known as hypertrophic pulmonary Digital clubbing is characterized by a focal bulbous osteoarthropathy (HPOA) based on the fact that majority enlargement of the terminal segments of the fingers of cases of HOA are due to malignant thoracic tumors. and/or toes due to proliferation of connective tissue The term “pulmonary” was later abandoned as it was between nail matrix and the distal phalanx. It results in realized that the skeletal syndrome may occur in several increase in both anteroposterior and lateral diameter of non‑pulmonary diseases and even may occur without the nails.[1] Clubbed fingers are also known as watch‑glass any underlying illness. -
Aspirin Intervention for the Reduction of Colorectal Cancer Risk (ASPIRED): a Study Protocol for a Randomized Controlled Trial David A
Drew et al. Trials (2017) 18:50 DOI 10.1186/s13063-016-1744-z STUDYPROTOCOL Open Access ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial David A. Drew1,2, Samantha M. Chin1,2, Katherine K. Gilpin1,2, Melanie Parziale1,2, Emily Pond1,2, Madeline M. Schuck1,2, Kathleen Stewart2, Meaghan Flagg3, Crystal A. Rawlings3, Vadim Backman4, Peter J. Carolan2, Daniel C. Chung2, Francis P. Colizzo III2, Matthew Freedman5, Manish Gala1,2, John J. Garber2, Curtis Huttenhower6, Dmitriy Kedrin2, Hamed Khalili1,2, Douglas S. Kwon3, Sanford D. Markowitz8, Ginger L. Milne9, Norman S. Nishioka2, James M. Richter2, Hemant K. Roy10, Kyle Staller1,2, Molin Wang6,7,11 and Andrew T. Chan1,2,5,11,12* Abstract Background: Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined. Moreover, the precise mechanisms by which aspirin reduces the risk of cancer are unclear. We recently launched the ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED) trial to address these uncertainties. Methods/design: ASPIRED is a prospective, double-blind, multidose, placebo-controlled, biomarker clinical trial of aspirin use in individuals previously diagnosed with colorectal adenoma. Individuals (n = 180) will be randomized in a 1:1:1 ratio to low-dose (81 mg/day) or standard-dose (325 mg/day) aspirin or placebo. At two study visits, participants will provide lifestyle, dietary and biometric data in addition to urine, saliva and blood specimens. Stool, grossly normal colorectal mucosal biopsies and cytology brushings will be collected during a flexible sigmoidoscopy without bowel preparation. -
Downloaded from Bioscientifica.Com at 09/25/2021 12:14:58PM Via Free Access
ID: 19-0149 8 6 Q Pang et al. PHO patients with soft tissue 8:6 736–744 giant tumor caused by HPGD mutation RESEARCH The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation Qianqian Pang1,2, Yuping Xu1,3, Xuan Qi1, Yan Jiang1, Ou Wang1, Mei Li1, Xiaoping Xing1, Ling Qin2 and Weibo Xia1 1Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China 2Musculoskeletal Research Laboratory and Bone Quality and Health Assessment Centre, Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong 3Department of Endocrinology, The First Affiliated Hospital of Shanxi Medicalniversity, U Taiyuan, Shanxi, China Correspondence should be addressed to L Qin or W Xia: [email protected] or [email protected] Abstract Background: Primary hypertrophic osteoarthropathy (PHO) is a rare genetic multi-organic Key Words disease characterized by digital clubbing, periostosis and pachydermia. Two genes, f primary hypertrophic HPGD and SLCO2A1, which encodes 15-hydroxyprostaglandin dehydrogenase (15-PGDH) osteoarthropathy and prostaglandin transporter (PGT), respectively, have been reported to be related to f PHO PHO. Deficiency of aforementioned two genes leads to failure of prostaglandin E2 (PGE2) f HPGD mutation degradation and thereby elevated levels of PGE2. PGE2 plays an important role in f soft tumor tumorigenesis. Studies revealed a tumor suppressor activity of 15-PGDH in tumors, such f COX2 selective inhibitor treatment as lung, bladder and breast cancers. However, to date, no HPGD-mutated PHO patients presenting concomitant tumor has been documented. -
New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10. -
Solarbio Catalogue with PRICES
CAS Name Grade Purity Biochemical Reagent Biochemical Reagent 75621-03-3 C8390-1 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS Ultra Pure Grade 1g 75621-03-3 C8390-5 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS 5g 57-09-0 C8440-25 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 25g 57-09-0 C8440-100 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 100g 57-09-0 C8440-500 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 500g E1170-100 0.5M EDTA (PH8.0) 100ml E1170-500 0.5M EDTA (PH8.0) 500ml 6381-92-6 E8030-100 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 100g 6381-92-6 E8030-500 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 500g 6381-92-6 E8030-1000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 1kg 6381-92-6 E8030-5000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 5kg 60-00-4 E8040-100 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 100g 60-00-4 E8040-500 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 500g 60-00-4 E8040-1000 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 1kg 67-42-5 E8050-5 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 5g 67-42-5 E8050-10 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 10g 50-01-1 G8070-100 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 100g 50-01-1 G8070-500 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 500g 56-81-5 -
Taqman® Human and Rat Inflammation Arrays
TaqMan® Gene Signature Arrays TaqMan® Human and Rat Inflammation Arrays These arrays are part of a collection of TaqMan® Gene Signature Group Assays Human Gene Symbols Arrays that enable analysis of hundreds of TaqMan® Gene Channels 7 Expression Assays on a micro fluidic card with minimal effort. L-type calcium 5 CACNA1C, CACNA1D, CACNA2D1, CACNB2, CACNB4 Inflammation is the body’s response to infection, irritation Ligand gated 2 HTR3A, HTR3B or injury; characterized by redness, heat, swelling, pain and Enzymes and inhibitors 41 possible dysfunction of the organs involved. It can be defined Inhibitor 1 A2M Lipase 15 CES1, PLA2G1B, PLA2G2A, PLA2G5, as an innate immune response manifested by increased blood PLCB2–4, PLCD1, PLCG1, PLCG2, supply and vascular permeability. This allows fluid and white PLA2G7, PLA2G10, PLA2G4C, blood cells to leave the intravascular compartment and move PLA2G2D, PLCE1 Kinase 4 MAPK1, MAPK3, MAPK8, MAPK14 to the site of injury or infection. Nitric oxide synthase 1 NOS2A Phosphodiesterase 4 PDE4A–D Inflammation is associated with a wide range of disorders Prostaglandin metabolism 9 ALOX12, ALOX5, HPGD, LTA4H, including asthma, allergy, rheumatoid arthritis, gout, sepsis, LTC4S, PTGIS, PTGS1 (COX1), PTGS2 (COX2), TBXAS1 autoimmune disease, cardiovascular disease, diabetes, Protease 7 KLK3, CASP1, KLK1, KLK2, neurologic disease and cancer. Medications targeting KLKB1, KLK14, KLK15 inflammatory diseases include NSAIDS, corticosteroids, Factors 9 ANXA1, ANXA3, ANXA5, TNFSF5, H1-receptor antagonists and ß2-selective adrenergic drugs. IL13, KNG1, NFKB1, TNFSF13B, TNF Current treatments tend to have limited efficacy because Receptors 35 they target symptoms or impair the immune response. GPCR 18 ADRB1, ADRB2, BDKRB1, BDKRB2, CYSLTR1, HRH1–3, LTB4R, An increasing number of new drugs and protein therapies LTB4R2, MC2R (missing on rat are being developed. -
Sarcoidosis Mimicking Lipodermatosclerosis
Sarcoidosis Mimicking Lipodermatosclerosis Carol L. Huang, MD; Diya F. Mutasim, MD The clinical presentation of cutaneous sarcoidosis We describe the case of a woman who presented is highly variable. Rare presentations include with unilateral ulcerating sarcoidosis of the lower leg ulcerated plaques, morpheaform lesions, and uni- with progressive fibrosis and edema mimicking lipo- lateral lower extremity edema. We report the dermatosclerosis. The presentation is unique in that case of a woman who presented with unilateral the patient exhibited all 3 of the rare manifestations ulcerating sarcoidosis of the lower leg with pro- of sarcoidosis (ulceration, unilateral edema, and fibro- gressive fibrosis and edema mimicking lipoder- sis), with morphologic similarity to lipodermato- matosclerosis. This case is unique in that the sclerosis. To our knowledge, this unique presentation patient exhibited all 3 of the rare manifestations of has not been previously reported in the literature. sarcoidosis; to our knowledge, this presentation has not been previously reported in the literature. Case Report Cutis. 2005;75:322-324. A 52-year-old African American woman with a 5-year history of a slowly enlarging lesion on the left lower leg reported tenderness, swelling, and ystemic sarcoidosis is a chronic granulomatous burning in the area. She had a history of pulmonary disease that involves the skin in 25% of sarcoidosis, and the diagnosis was confirmed by S affected patients. The clinical presentation of results of transbronchial biopsy; she had been taking cutaneous sarcoidosis is variable and includes both prednisone 20 to 40 mg/d for the pulmonary sar- specific and nonspecific lesions. Specific lesions coidosis. -
58 Yo Woman Referred for Unresponsive Drug Rash • Review Treatment Options
12:50 - 1:50pm Disclosures Can't Miss Dermatology Diagnoses: The following relationships exist related to this presentation: Cutaneous Manifestations of ► Daniela Kroshinsky, MD MPH: No financial relationships to disclose. Systemic Disease SPEAKER Daniela Kroshinsky, MD MPH Off-Label/Investigational Discussion ► In accordance with pmiCME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Overview • Identify cutaneous manifestations of systemic disease and their associated risk factors 58 yo woman referred for unresponsive drug rash • Review treatment options • Learn other mimicking cutaneous conditions Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. Dermatomyositis • Ragged cuticles, nail fold telangiectasias • Extensor limb rash, including knuckles • Shawl‐distribution poikiloderma with extension into scalp • Periorbital edema, heliotrope rash • Diffuse facial erythema, malar erythema • Holster sign • More violaceous and pruritic than lupus • Erosions, ulcerations Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. Forms • Resembles polymyositis; symmetric proximal muscles usually • Skin findings precede muscle in most cases • Classic (with muscle disease) • Amyopathic (myositis may evolve over time) • Hypomyopathic dermatomyositis (no clinical muscle weakness, but myositis present on radiographic or laboratory -
Nails in Systemic Disease
CME: DERMATOLOGY Clinical Medicine 2021 Vol 21, No 3: 166–9 Nails in systemic disease Authors: Charlotte E GollinsA and David de BerkerB A change in colour, size, shape or texture of finger- and MatrixCuticle toenails can be an indicator of underlying systemic disease. Nail plate An appreciation of these nail signs, and an ability to interpret them when found, can help guide diagnosis and management Nail bed of a general medical patient. This article discusses some ABSTRACT common, and some more rare, nail changes associated with systemic disease. Proximal nail fold Introduction Cuticle Examination of nails is a skill that, although emphasised when Matrix (lunula) revising for general medical exams, can be overlooked in day- Nail plate Lateral nail fold to-day practice. The value of noticing, understanding and Onychocorneal interpreting nail changes can positively add to clinical practice as band these signs can provide valuable clues to a diagnosis. Here we present a brief overview of selected common and rarer Fig 1. Anatomy of the nail plate. nail abnormalities associated with systemic conditions, as well as a limited explanation of the pathophysiology of some of the changes. Anatomy of the nail unit located in the distal third of the nail plate. They are caused The nail unit (Fig 1) is an epithelial skin appendage composed by damage to capillaries within the nail bed, which have a of the hardened nail plate surrounded by specialised epithelial longitudinal orientation, leading to their linear appearance. In the surfaces that contribute to its growth and maintenance.1 The nail case of bacterial endocarditis, this damage is likely to be caused by plate is formed of keratinised epithelial cells. -
Prostaglandin E2 Increase in Pachydermoperiostosis Without 15-Hydroprostaglandin Dehydrogenase Mutations
118 Letters to the Editor Prostaglandin E2 Increase in Pachydermoperiostosis Without 15-hydroprostaglandin Dehydrogenase Mutations Kyoko Nakahigashi1, Atsushi Otsuka1*, Hiromi Doi1, Satsuki Tanaka2, Yoshiaki Okajima3, Hironori Niizeki4, Asami Hiraki- yama4, Yoshiki Miyachi1 and Kenji Kabashima1* 1Department of Dermatology, Kyoto University, Graduate School of Medicine, 54 Shogoin-Kawara, Sakyo, Kyoto 606-8507, 2Department of Diabetes and Endocrinology, and 3Department of Orthopedic Surgery, Osaka Saiseikai Nakatsu Hospital, Osaka, and 4Department of Dermatology, National Center for Child Health and Development, Tokyo, Japan. *E-mails: [email protected], [email protected] Accepted April 10, 2012. Pachydermoperiostosis (PDP), a form of primary hyper head, and marked clubbing of the fingers (Fig. 1a, b). trophic osteoarthropathy (PHO), is a rare hereditary No other remarkable physical findings were observed, disease diagnosed by the presence of the triad of digital and he did not present seborrhoea, acne, folliculitis or clubbing, periostosis, and pachydermia (1, 2). Elevated hyperhidrosis. Family history was non-contributory. prostaglandin E2 (PGE2) levels with cytokinemediated All laboratory tests including serum levels of growth tissue remodelling and vascular stimulation may underlie hormone, insulinlike growth factor1, thyroid fun PHO and is associated with the features such as hyper ction, immunoglobulins, haemoglobin A1c, and bone hidrosis, acroosteolysis, pachydermia, periostosis and mineral metabolism were within normal ranges, which arthritis (3). Homozygous and compound heterozygous ruled out thyroid acropathy and acromegaly. Magnetic germline mutations in the 15hydroxyprostaglandin resonance imaging of the head revealed cutis verticis dehydrogenase (HPGD) gene encoding the major PGE2 gyrate (Fig. 1c). X-ray examination of the knee region catabolizing enzyme have been described in familial PHO revealed periostosis with cortical thickening and ec cases (4).